In therapeutic terms, Dmab, an anti-RANKL medication approved for the treatment of osteoporosis, may also prove suitable in the future for the treatment of metabolic diseases, e.g., obesity, T2DM, and NAFLD. This evidence concerns the gene TNFSF11 and Other metabolic disease.